Delmar Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Aug 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol (US 9,066,918) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Jan 21, 2027The maintenance fee for Method of synthesis of substituted hexitols such as dianhydrogalactitol (US 9,085,544) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Feb 8, 2027The maintenance fee for Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas (US 11,717,505) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Methods for analysis and resolution of preparations of dianhydrogalactitol and derivatives or analogs thereof (US 10,591,445) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,921,585 | Method of Synthesis of Substituted Hexitols Such as Dianhydrogalactitol In force · Medium confidence | In force | Medium confidence | |
| US 9,066,918 | Methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol In force · USPTO record | In force | USPTO record | |
| US 9,085,544 | Method of synthesis of substituted hexitols such as dianhydrogalactitol In force · USPTO record | In force | USPTO record | |
| US 9,029,164 | Analytical methods for analyzing and determining impurities in dianhydrogalactitol In force · USPTO record | In force | USPTO record | |
| US 11,234,955 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma In force · USPTO record | In force | USPTO record | |
| US 11,026,914 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor In force · USPTO record | In force | USPTO record | |
| US 11,541,027 | Use of Dianhydrogalactitol and Analogs or Derivatives Thereof in Combination with Platinum-Containing Antineoplastic Agents to Treat Non-Small-Cell Carcinoma of the Lung and Brain Metastases In force · Medium confidence | In force | Medium confidence | |
| US 10,145,824 | Analytical methods for analyzing and determining impurities in dianhydrogalactitol In force · USPTO record | In force | USPTO record | |
| US 10,201,521 | Use of Substituted Hexitols Including Dianhydrogalactitol and Analogs to Treat Neoplastic Disease and Cancer Stem and Cancer Stem Cells Including Glioblastoma Multiforme and Medulloblastoma In force · High confidence | In force | High confidence | |
| US 10,591,445 | Methods for analysis and resolution of preparations of dianhydrogalactitol and derivatives or analogs thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 11: 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 12 no status recorded